British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition ...

Having scored approval for Nucala in COPD, GSK has signed a $12 billion deal to strengthen the pharma’s offering for the respiratory condition.

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and inflammation.

GSK is taking to the airwaves to talk RSV, presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games.

Drugmaker GSK will be paid up to £372million after settling a patent row over Covid vaccines in the US. The London-listed pharmaceuticals giant – previously known as Glaxosmithkline – and ...

GSK is sticking to its projection to generate more than 40 billion pounds of sales in 2031, regardless of whether it regains U.S. approval of Blenrep.

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the mRNA vaccine technology that was at the forefront of the world's fight ...

GSK also would benefit from reduced milestones and a reduction in royalties payable in respect of GSK sales of mRNA influenza, Covid-19 and influenza/Covid-19 combination products outside of the US.

Glaxo (GSK) delivered earnings and revenue surprises of +9.82% and +3.25%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?